Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of ...

Liver transplantation is the sole curative option for HCC, but new therapies prompt reconsideration of transplant timing and ...

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

The Boehringer Ingelheim Foundation is providing 600,000 Euros in funding for basic research into new approaches to the treatment of liver fibrosis and fatty liver hepatitis.

The city admits that the temporary measure project is still “at a planning stage” and only now being escalated to the supply ...

The company said that its test could overcome sensitivity issues with ultrasound and serum alpha-fetoprotein assays that are used to monitor at-risk patients.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

The definition of preventive healthcare can be broad and confusing. To figure out what it actually is, we reached out to ...

FORT LAUDERDALE, FL, UNITED STATES, April 29, 2025 /EINPresswire.com/ -- Beachcomber Intensive Outpatient, a leading provider ...

AbbVie today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes ...